Notable non-ccRCC subtype-specific events include: the signature chromosomal losses and TP53 mutations in chRCC (3/3 cases), chr7/17 gain (8/13 cases), and MET mutations (3/13 cases) in pRCC, TSC gene mutations in ESCRCC (2/2 cases) and AML tumors (2/2 cases), and the TFE3 gene fusion in a TRCC case. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.